Skip to Main Content
Contribute Try STAT+ Today

On Friday, the Food and Drug Administration is supposed to announce its decision on whether or not to approve the first treatment for the fatty liver disease known as NASH. But that plan has apparently been postponed for reasons that are still not clear. The FDA hasn’t offered an explanation, nor has Intercept Pharmaceuticals, the maker of the NASH drug under review.

Reached on Monday, an Intercept spokesperson said the company intends to provide an update on “any material developments with respect to its regulatory timeline,” but has nothing to disclose at this time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.